| __timestamp | PTC Therapeutics, Inc. | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 79838000 | 5758000 |
| Thursday, January 1, 2015 | 121816000 | 8423000 |
| Friday, January 1, 2016 | 117633000 | 11986000 |
| Sunday, January 1, 2017 | 4577000 | 15215000 |
| Monday, January 1, 2018 | 12670000 | 15356000 |
| Tuesday, January 1, 2019 | 12135000 | 16660000 |
| Wednesday, January 1, 2020 | 18942000 | 52459000 |
| Friday, January 1, 2021 | 32328000 | 75061000 |
| Saturday, January 1, 2022 | 44678000 | 87221000 |
| Sunday, January 1, 2023 | 65486000 | 83779000 |
Igniting the spark of knowledge
In the dynamic world of biopharmaceuticals, understanding cost structures is crucial. This analysis delves into the cost of revenue trends for PTC Therapeutics, Inc. and Supernus Pharmaceuticals, Inc. from 2014 to 2023. Over this period, PTC Therapeutics saw a significant fluctuation, with costs peaking in 2015 at approximately 121 million, then stabilizing around 65 million by 2023. In contrast, Supernus Pharmaceuticals experienced a steady increase, with costs rising from about 6 million in 2014 to nearly 87 million in 2022, marking a 14-fold increase. This divergence highlights differing strategic approaches: PTC's volatile cost management versus Supernus's consistent growth. Such insights are invaluable for investors and stakeholders aiming to navigate the complexities of the biopharmaceutical sector.
AbbVie Inc. vs Supernus Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Pfizer Inc. vs PTC Therapeutics, Inc.
Cost of Revenue: Key Insights for Pfizer Inc. and Supernus Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Zoetis Inc. and PTC Therapeutics, Inc.
Cost of Revenue Trends: United Therapeutics Corporation vs PTC Therapeutics, Inc.
Cost of Revenue: Key Insights for Halozyme Therapeutics, Inc. and PTC Therapeutics, Inc.
Cost Insights: Breaking Down PTC Therapeutics, Inc. and Perrigo Company plc's Expenses
PTC Therapeutics, Inc. vs HUTCHMED (China) Limited: Efficiency in Cost of Revenue Explored
Revenue Showdown: PTC Therapeutics, Inc. vs Supernus Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for PTC Therapeutics, Inc. and Dyne Therapeutics, Inc.
Analyzing Cost of Revenue: Perrigo Company plc and Supernus Pharmaceuticals, Inc.
Cost Insights: Breaking Down Supernus Pharmaceuticals, Inc. and Amphastar Pharmaceuticals, Inc.'s Expenses